模型类器官为胰腺导管癌提供了新的研究机会。
Model organoids provide new research opportunities for ductal pancreatic cancer.
作者信息
Boj Sylvia F, Hwang Chang-Il, Baker Lindsey A, Engle Dannielle D, Tuveson David A, Clevers Hans
机构信息
Hubrecht Institute; Royal Netherlands Academy of Arts and Sciences (KNAW); University Medical Center Utrecht and Cancer Genomics; Utrecht, the Netherlands; Foundation Hubrecht Organoid Technology; Utrecht, the Netherlands.
Cold Spring Harbor Laboratory; Cold Spring Harbor, NY USA; Lustgarten Foundation Pancreatic Cancer Research Laboratory; Cold Spring Harbor, NY USA.
出版信息
Mol Cell Oncol. 2015 Feb 23;3(1):e1014757. doi: 10.1080/23723556.2015.1014757. eCollection 2016 Jan.
Abstract
We recently established organoid models from normal and neoplastic murine and human pancreas tissues. These organoids exhibit ductal- and disease stage-specific characteristics and, after orthotopic transplantation, recapitulate the full spectrum of tumor progression. Pancreatic organoid technology provides a novel platform for the study of tumor biology and the discovery of potential biomarkers, therapeutics, and personalized medicine strategies.
摘要
我们最近从正常和肿瘤性小鼠及人类胰腺组织中建立了类器官模型。这些类器官表现出导管和疾病阶段特异性特征，并且在原位移植后，概括了肿瘤进展的全谱。胰腺类器官技术为肿瘤生物学研究以及潜在生物标志物、治疗方法和个性化医学策略的发现提供了一个新平台。
相似文献
1
Model organoids provide new research opportunities for ductal pancreatic cancer.
Mol Cell Oncol. 2015 Feb 23;3(1):e1014757. doi: 10.1080/23723556.2015.1014757. eCollection 2016 Jan.
2
Organoid models of human and mouse ductal pancreatic cancer.
Cell. 2015 Jan 15;160(1-2):324-38. doi: 10.1016/j.cell.2014.12.021. Epub 2014 Dec 31.
3
Organoid technology and applications in cancer research.
J Hematol Oncol. 2018 Sep 15;11(1):116. doi: 10.1186/s13045-018-0662-9.
4
Organoids from the Human Fetal and Adult Pancreas.
Curr Diab Rep. 2019 Dec 11;19(12):160. doi: 10.1007/s11892-019-1261-z.
5
Preclinical Modelling of PDA: Is Organoid the New Black?
Int J Mol Sci. 2019 Jun 5;20(11):2766. doi: 10.3390/ijms20112766.
6
Human pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling.
Gut. 2017 Mar;66(3):473-486. doi: 10.1136/gutjnl-2016-312423. Epub 2016 Sep 15.
7
Pancreas 3D Organoids: Current and Future Aspects as a Research Platform for Personalized Medicine in Pancreatic Cancer.
Cell Mol Gastroenterol Hepatol. 2017 Dec 16;5(3):289-298. doi: 10.1016/j.jcmgh.2017.12.004. eCollection 2018 Mar.
8
Preclinical models of pancreatic ductal adenocarcinoma.
J Pathol. 2016 Jan;238(2):197-204. doi: 10.1002/path.4651. Epub 2015 Nov 14.
9
Pancreatic Organoids for Regenerative Medicine and Cancer Research.
Front Cell Dev Biol. 2022 May 3;10:886153. doi: 10.3389/fcell.2022.886153. eCollection 2022.
10
Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Samples.
Front Oncol. 2019 Sep 13;9:875. doi: 10.3389/fonc.2019.00875. eCollection 2019.
引用本文的文献
1
Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcinoma.
Int J Cancer. 2025 Aug 15;157(4):760-772. doi: 10.1002/ijc.35443. Epub 2025 Apr 28.
2
Treatment Response to Oncolytic Virus in Patient-Derived Breast Cancer and Hypopharyngeal Cancer Organoids: Evaluation via a Microfluidics Organ-on-a-Chip System.
Bioengineering (Basel). 2025 Feb 4;12(2):146. doi: 10.3390/bioengineering12020146.
3
Perspective of 3D culture in medicine: transforming disease research and therapeutic applications.
Front Bioeng Biotechnol. 2024 Dec 19;12:1491669. doi: 10.3389/fbioe.2024.1491669. eCollection 2024.
4
Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma.
Epigenomes. 2024 Nov 3;8(4):41. doi: 10.3390/epigenomes8040041.
5
Design principles and therapeutic applications of novel synthetic WNT signaling agonists.
iScience. 2024 May 8;27(6):109938. doi: 10.1016/j.isci.2024.109938. eCollection 2024 Jun 21.
6
Landscape of human organoids: Ideal model in clinics and research.
Innovation (Camb). 2024 Apr 1;5(3):100620. doi: 10.1016/j.xinn.2024.100620. eCollection 2024 May 6.
7
Orthotopic and metastatic tumour models in preclinical cancer research.
Pharmacol Ther. 2024 May;257:108631. doi: 10.1016/j.pharmthera.2024.108631. Epub 2024 Mar 11.
8
BRAF in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability.
Sci Adv. 2023 Sep;9(35):eade7486. doi: 10.1126/sciadv.ade7486. Epub 2023 Sep 1.
9
USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities.
Cell Rep Med. 2023 Apr 18;4(4):101007. doi: 10.1016/j.xcrm.2023.101007. Epub 2023 Apr 7.
10
Engineering functional 3-dimensional patient-derived endocrine organoids for broad multiplatform applications.
Surgery. 2023 Jan;173(1):67-75. doi: 10.1016/j.surg.2022.09.027. Epub 2022 Nov 16.
本文引用的文献
1
Organoid models of human and mouse ductal pancreatic cancer.
Cell. 2015 Jan 15;160(1-2):324-38. doi: 10.1016/j.cell.2014.12.021. Epub 2014 Dec 31.
2
Pancreatic adenocarcinoma.
N Engl J Med. 2014 Nov 27;371(22):2140-1. doi: 10.1056/NEJMc1412266.
3
Organoid cultures derived from patients with advanced prostate cancer.
Cell. 2014 Sep 25;159(1):176-187. doi: 10.1016/j.cell.2014.08.016. Epub 2014 Sep 4.
4
Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis.
EMBO J. 2013 Oct 16;32(20):2708-21. doi: 10.1038/emboj.2013.204. Epub 2013 Sep 17.
5
In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration.
Nature. 2013 Feb 14;494(7436):247-50. doi: 10.1038/nature11826. Epub 2013 Jan 27.
6
Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.
Gastroenterology. 2011 Nov;141(5):1762-72. doi: 10.1053/j.gastro.2011.07.050. Epub 2011 Sep 2.
7
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
Science. 2009 Jun 12;324(5933):1457-61. doi: 10.1126/science.1171362. Epub 2009 May 21.
8
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche.
Nature. 2009 May 14;459(7244):262-5. doi: 10.1038/nature07935. Epub 2009 Mar 29.
9
The mighty mouse: genetically engineered mouse models in cancer drug development.
Nat Rev Drug Discov. 2006 Sep;5(9):741-54. doi: 10.1038/nrd2110. Epub 2006 Aug 18.
10
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.
Br J Cancer. 2001 May 18;84(10):1424-31. doi: 10.1054/bjoc.2001.1796.
Zotero 插件